HKU Scholars Hub: Browsing DSpace

Browsing by Author Thongprasert, S

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 6 of 6

	Title	Author(s)	Issue Date	Views
	Impact of epidermal growth factor receptor inhibitor in non-small cell lung cancer on progression-free an overall survival: a meta-analysis Journal:Journal of the National Cancer Institute	Lee, CH Brown, C Gralla, R Hirsh, V Thongprasert, S Tsai, CM Tan, EH Ho, JCM Chu, DT Zaatar, A Sanchez, JO Vu, VV Au, JSK Inoue, A Lee, SM Gebski, V Yang, JCH	2013	68
	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-lung cancer (FASTACT-2): a randomised, double-blind trial Journal:Lancet Oncology	Wu, YL Lee, JS Thongprasert, S Yu, CJ Zhang, L Ladrera, G Srimuninnimit, V Sriuranpong, V Sandoval-Tan, J Zhu, Y Liao, M Zhou, C Pan, H Lee, VHF Chen, YM Sun, Y Margono, B Fuerte, F Chang, GC Seetalarom, K Wang, J Cheng, CK Syahruddin, E Qian, X Ho, JCM Kurnianda, J Liu, HE Jin, K Truman, M Bara, I Mok, T	2013	90
	Phase II study of two eribulin regimens in combination with erlotinib in patients (PTS) with previously treated advanced non-small cell lung cancer (NSCLC) Proceeding/Conference:Annals of Oncology	Geater, SL Ianotti, N Thongprasert, S Spira, A Smith, D Lee, V Lim, WT Gopalakrishna, P Reynolds, C Mok, TSK	2012	84
	Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer Journal:Annals of Oncology	Mok, TS Geater, SL Iannotti, N Thongprasert, S Spira, A Smith, D Lee, VHF Lim, WT Reyderman, L Wang, B	2014	48
	A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II Proceeding/Conference:Journal of Clinical Oncology	Mok, T Wu, YL Thongprasert, S Yu, CJ Zhang, L Ladrera, GE Srimuninnimit, V Sriuranpong, V Sandoval-Tan, J Zhu, Y Liao, M Zhou, C Pan, H Lee, V Chen, YM Sun, Y Margono, B Jin, K Truman, M Lee, JS	2012	164
	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma Journal:Hepatology	Cheng, AL Thongprasert, S Lim, HY Sukeepaisarnjaroen, W Yang, TS Wu, CC Chao, Y Chan, SL Kudo, M Ikeda, M Kang, YK Pan, H Numata, K Han, G Balsara, B Zhang, Y Rodriguez, AM Zhang, Y Wang, Y Poon, RTP	2016	93

Showing results 1 to 6 of 6